Workflow
实验分析仪器自主研发
icon
Search documents
莱伯泰科2025年中报简析:净利润同比下降11.53%,公司应收账款体量较大
Zheng Quan Zhi Xing· 2025-08-29 22:41
Core Viewpoint - The recent financial report of Laibotai Technology (688056) indicates a decline in revenue and net profit for the first half of 2025 compared to the previous year, raising concerns about the company's financial health and operational efficiency [1][3]. Financial Performance - Total revenue for the first half of 2025 was 192 million yuan, a decrease of 10.33% year-on-year [1]. - Net profit attributable to shareholders was 21.09 million yuan, down 11.53% year-on-year [1]. - In Q2 2025, total revenue was 92.91 million yuan, reflecting a 14.45% decline year-on-year, while net profit for the quarter was 8.33 million yuan, a significant drop of 32.12% [1]. - The gross profit margin improved slightly to 45.55%, an increase of 1.92% year-on-year, while the net profit margin decreased to 10.99%, down 1.33% year-on-year [1]. - Total operating expenses (sales, management, and financial expenses) amounted to 42.90 million yuan, representing 22.35% of revenue, an increase of 3.4% year-on-year [1]. Asset and Liability Management - Accounts receivable reached a significant level, with accounts receivable to net profit ratio at 142.89%, indicating potential liquidity issues [1][3]. - Cash and cash equivalents decreased to 266 million yuan, down 16.97% year-on-year [1]. - Interest-bearing liabilities increased by 36.18% to 1.01 million yuan [1]. Earnings and Cash Flow - Earnings per share (EPS) decreased to 0.32 yuan, down 8.57% year-on-year [1]. - Operating cash flow per share was -0.12 yuan, a drastic decline of 89.31% year-on-year [1]. - The company’s return on invested capital (ROIC) was reported at 4.07%, indicating weak capital returns compared to historical averages [3]. Business Model and Strategy - The company relies heavily on research and marketing for its performance, necessitating a deeper analysis of these driving factors [3]. - The company has focused on differentiated competition and collaboration, particularly in sample pretreatment equipment, before venturing into mass spectrometry development in 2019 [4].